Prediman K Shah

List of Publications by Year
in descending order

63 papers	4,827 citations	218662 26 h-index	128286 60 g-index
91 all docs	91 docs citations	91 times ranked	5601 citing authors

#	Article	IF	Citations
1	Coronary Plaque Disruption. Circulation, 1995, 92, 657-671.	1.6	2,863
2	Infections, atherosclerosis, and coronary heart disease. European Heart Journal, 2017, 38, 3195-3201.	2.2	185
3	Screening Asymptomatic Subjects for Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2010, 56, 98-105.	2.8	144
4	Tenascin-C Is Expressed in Macrophage-Rich Human Coronary Atherosclerotic Plaque. Circulation, 1999, 99, 1284-1289.	1.6	143
5	Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 66, 1431-1441.	2.8	116
6	Inflammation and Plaque Vulnerability. Cardiovascular Drugs and Therapy, 2009, 23, 31-40.	2.6	107
7	Molecular mechanisms of plaque instability. Current Opinion in Lipidology, 2007, 18, 492-499.	2.7	94
8	Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Diseaseâ€“Associated Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 886-897.	2.4	85
9	Active Oxygen Species and Lysophosphatidylcholine Are Involved in Oxidized Low Density Lipoprotein Activation of Smooth Muscle Cell DNA Synthesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 194-200.	2.4	73
10	Vaccine for Atherosclerosis. Journal of the American College of Cardiology, 2014, 64, 2779-2791.	2.8	70
11	Intercepting the Lipid-Induced Integrated Stress Response Reduces Atherosclerosis. Journal of the American College of Cardiology, 2019, 73, 1149-1169.	2.8	57
12	Immunomodulation of atherosclerosis with a vaccine. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 639-646.	3.3	46
13	Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. European Heart Journal, 2006, 28, 5-12.	2.2	46
14	Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiology Clinics, 2003, 21, 303-314.	2.2	43
15	Coronary Atherosclerosis T1-Weighed Characterization With Integrated Anatomical Reference. JACC: Cardiovascular Imaging, 2017, 10, 637-648.	5.3	43
16	Deficiency of GATA3-Positive Macrophages Improves Cardiac Function Following MyocardialÂInfarction or Pressure Overload Hypertrophy. Journal of the American College of Cardiology, 2018, 72, 885-904.	2.8	43
17	Cholesterol Lowering Modulates T Cell Function In Vivo and In Vitro. PLoS ONE, 2014, 9, e92095.	2.5	38
18	Intramyocardial Hemorrhage and the â€œWave Frontâ€•of Reperfusion Injury Compromising Myocardial Salvage. Journal of the American College of Cardiology, 2022, 79, 35-48.	2.8	38

#	Article	IF	Citations
19	Inflammation in atherosclerotic cardiovascular disease. F1000Research, 2019, 8, 1402.	1.6	37
20	Sex-Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor-Deficient Mice. JACC Basic To Translational Science, 2020, 5, 582-598.	4.1	36
21	CD8+CD25+ T cells reduce atherosclerosis in apoE(â^'/â^') mice. Biochemical and Biophysical Research Communications, 2014, 443, 864-870.	2.1	35
22	Vaccine against arteriosclerosis: an update. Therapeutic Advances in Vaccines, 2017, 5, 39-47.	2.7	34
23	Parallels between retinal and brain pathology and response to immunotherapy in old, lateâ€stage Alzheimer's disease mouse models. Aging Cell, 2020, 19, e13246.	6.7	32
24	Apolipoprotein A-I Mimetic Peptides: Potential Role in Atherosclerosis Management. Trends in Cardiovascular Medicine, 2005, 15, 291-296.	4.9	30
25	Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach. PLoS ONE, 2019, 14, e0213025.	2.5	28
26	Innate Immune Pathway Links Obesity to Insulin Resistance. Circulation Research, 2007, 100, 1531-1533.	4.5	26
27	Declining Admissions for Acute Cardiovascular Illness. Journal of the American College of Cardiology, 2020, 76, 289-291.	2.8	23
28	Plaque Disruption and Coronary Thrombosis: New Insight into Pathogenesis and Prevention. Clinical Cardiology, 1997, 20, II-38.	1.8	22
29	Chlamydia and Lipids Engage a CommonÂSignaling Pathway That Promotes Atherogenesis. Journal of the American College of Cardiology, 2018, 71, 1553-1570.	2.8	22
30	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.6	22
31	Autocrine Induction of DNA Synthesis by Mechanical Injury of Cultured Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 187-193.	2.4	19
32	High-Density Lipoprotein Mimetics: Focus on Synthetic High-Density Lipoprotein. American Journal of Cardiology, 2007, 100, S62-S67.	1.6	18
33	Targeting endogenous apo A-Iâ€"a new approach for raising HDL. Nature Reviews Cardiology, 2011, 8, 187-188.	13.7	18
34	In Pursuit of an Atherosclerosis Vaccine. Circulation Research, 2018, 123, 1121-1123.	4.5	15
35	Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. Catheterization and Cardiovascular Interventions, 1999, 48, 430-434.	1.7	13
36	Sustained benefits of oral pentaerythritol tetranitrate on ventricular function in chronic congestive heart failure. Clinical Pharmacology and Therapeutics, 1980, 28, 436-440.	4.7	12

#	Article	IF	Citations
37	Jekyll and Hyde of HDL: a lipoprotein with a split personality. European Heart Journal, 2013, 34, 3531-3534.	2.2	12
38	Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along With Apo A-I Milano Gene Therapy on Regression of Atherosclerosis. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 320-328.	2.0	12
39	Emerging HDL-based therapies for atherothrombotic vascular disease. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 60-70.	0.9	11
40	Vaccination for atherosclerosis: a novel therapeutic paradigm. Expert Review of Vaccines, 2004, 3, 711-716.	4.4	9
41	Immunization with an ApoB-100 Related Peptide Vaccine Attenuates Angiotensin-II Induced Hypertension and Renal Fibrosis in Mice. PLoS ONE, 2015, 10, e0131731.	2.5	8
42	The Role of T Cells Reactive to the Cathelicidin Antimicrobial Peptide LL-37 in Acute Coronary Syndrome and Plaque Calcification. Frontiers in Immunology, 2020, 11, 575577.	4.8	8
43	Thrombogenic risk factors for atherothrombosis. Reviews in Cardiovascular Medicine, 2006, 7, 10-6.	1.4	8
44	Chronic infections and atherosclerosis/thrombosis. Current Atherosclerosis Reports, 2002, 4, 113-119.	4.8	7
45	Can Carotid Plaque Predict Coronary Plaque?. JACC: Cardiovascular Imaging, 2013, 6, 1168-1171.	5.3	7
46	Immunotherapy for atherosclerosis: an emerging paradigm. Reviews in Cardiovascular Medicine, 2004, 5, 194-203.	1.4	7
47	Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?. Reviews in Cardiovascular Medicine, 2011, 12, e55-9.	1.4	7
48	Hemodynamic effects of intravenous timolol in coronary artery disease. Clinical Pharmacology and Therapeutics, 1979, 26, 330-338.	4.7	6
49	Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease. Expert Opinion on Investigational Drugs, 2000, 9, 2139-2146.	4.1	6
50	IL-7R blockade reduces post-myocardial infarction-induced atherosclerotic plaque inflammation in ApoEâˆ’/- mice. Biochemistry and Biophysics Reports, 2019, 19, 100647.	1.3	6
51	Immunogenetics of Atherosclerosisâ€"Link between Lipids, Immunity, and Genes. Current Atherosclerosis Reports, 2020, 22, 53.	4.8	6
52	Comparative Antiatherogenic Effects of Intravenous AAV8- and AAV2-Mediated ApoA-IMilano Gene Transfer in Hypercholesterolemic Mice. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 66-75.	2.0	5
53	Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases. Therapeutic Advances in Vaccines, 2014, 2, 56-66.	2.7	4
54	Promoting athero-protective immunity by vaccination with low density lipoprotein-derived antigens. Atherosclerosis, 2021, 335, 89-97.	0.8	4

#	Article	IF	Citations
55	Does Reduced Carotid Intima Media Thickness Progression Predict Cardiovascular Risk Reduction?. Circulation, 2020, 142, 643-644.	1.6	3
56	Sex as a Determinant of Responses to a Coronary Artery Disease Self-Antigen Identified by Immune-Peptidomics. Frontiers in Immunology, 2020, 11, 694.	4.8	3
57	Noncalcified Plaque in Cardiac CT: Quantification and Clinical Implications. Current Cardiovascular Imaging Reports, 2015, 8, 1.	0.6	2
58	Sugar-Sweetened Beverage and Vascular Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1020-1021.	2.4	2
59	Aging and GATA3-positive macrophages. Aging, 2019, 11, 2179-2180.	3.1	2
60	Plaque Disruption: Pathogenesis and Prevention. Journal of Thrombosis and Thrombolysis, 1998, 5, S89-S97.	2.1	0
61	Oxidized lipoprotein autoimmunity: an emerging drug target in cardiovascular disease. Future Lipidology, 2006, 1, 321-330.	0.5	0
62	Ranolazine: a new drug and a new paradigm for management of myocardial ischemia and angina. Reviews in Cardiovascular Medicine, 2004, 5, 186-8.	1.4	0
63	Retina mirrors brain pathology and response to GA immunotherapy in advanced stage AD-model mice.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055329.	0.8	0